United States Pharmaceutical Licensing

Pharmaceutical compliance in the United States is divided by activity, product and location, rather than covered by a single nationwide licence. Retail dispensing is primarily governed by the pharmacy licensing system of the state of operation; prescription drug wholesalers and third-party logistics providers must comply with both state licensing and the DSCSA authorised trading partner framework; manufacturing, repackaging or relabelling triggers federal obligations such as FDA establishment registration, drug listing and CGMP.

Foreign investment, corporate form, minimum capital, premises area and local entity requirements cannot be summarised in this guide as uniform nationwide rules. Confirm each requirement according to the intended state, actual ownership arrangements, whether deliveries will be made to patients in that state, whether controlled substances will be held and the specific product categories. California collects ownership, financial and management-control information in pharmacy applications; this is an example from that state only and cannot be extrapolated to the entire United States.

— First map the business flows: identify the states and entities involved in manufacturing/repackaging, imports, warehousing and logistics, wholesale, online delivery and pharmacy dispensing.

— List FDA registration and listing, product marketing authorisation, state facility licences, individual professional licences and DEA registration as separate workstreams.

FDA’s roles include drug establishment registration and listing, product marketing applications, import review, CGMP and DSCSA supply chain security. The FDA establishment registration database is different from the wholesaler/3PL annual reporting database; the former does not include wholesalers and 3PLs, and submissions to the latter do not constitute FDA approval or a compliance determination.

DEA oversees controlled substance registrations. State pharmacy boards or other state licensing authorities oversee state licences for pharmacies, wholesalers and relevant personnel. In California, for example, changes to responsible persons and facilities for pharmacies, wholesalers and 3PLs are handled through the state board’s processes; requirements in other states must be checked separately.

— Verify licences and registrations with FDA, DEA and state authorities separately.

Retail pharmacy facility licensing is not a substitute for FDA drug establishment registration; verify requirements with the pharmacy board or designated licensing authority in the intended state of operation. The California example shows that the board may issue pharmacy licences to individuals, partnerships, corporations, limited liability companies and other entities, and may investigate information in applications concerning ownership, finances, beneficial owners and management-control personnel; each pharmacy must have a PIC responsible for day-to-day operations. The scope of this investigation is not a uniform nationwide requirement.

An out-of-state pharmacy that mails, transports or delivers prescription drugs to California residents must also hold a valid licence in its state of residence and a California nonresident pharmacy licence. This example shows that an out-of-state e-commerce or delivery operation cannot be assessed solely by reference to its home-state pharmacy licence; for an actual project, check requirements state by state based on the patients’ locations, dispensing locations and logistics model.

— Distinguish dispensing to patients from wholesale supply to authorised customers, and verify licensing requirements based on the patients’ destination state.

The DSCSA establishes an electronic, package-level identification and tracing framework for certain prescription drugs, and requires relevant manufacturers, repackagers, wholesalers and dispensers to meet authorized trading partner requirements. FDA advises checking the relevant state licensing website to confirm that a wholesaler/3PL has an active licence, and also checking whether it has submitted a report to FDA’s annual reporting database.

In the California example, an entity must hold a wholesaler licence before selling, distributing, brokering the sale of, or returning prescription drugs to an authorized business or professional; wholesalers generally may not sell directly to patients. If a business only arranges warehousing or logistics and does not take ownership, it must still first determine whether it qualifies as a 3PL; it cannot rule out DSCSA and state licensing requirements merely because it is called a “logistics” business.

— Verify licence status and authorized trading partner status for each warehouse, business location and state of operation.

FDA requires domestic and foreign establishments that manufacture, repack or relabel drugs in the United States to register their establishments and list drugs sold commercially. DECRS states that establishments should register within five days of beginning operations and complete annual renewal submissions between 1/10 and 31/12 each year; registration status may be removed from the database in cases such as enforcement action, expiry, cancellation or failure to submit.

Manufacturing is not simply a matter of filing a registration. FDA CGMP requirements call for appropriate design, monitoring and control of processes and facilities; a quality system; suitable materials and procedures; investigation of deviations; a reliable testing laboratory; and assurance of facility conditions, equipment maintenance and calibration, personnel qualifications and training, and process reproducibility. Reviews of new drug or generic drug marketing applications also examine whether the manufacturer has the necessary facilities, equipment and capabilities.

— Determine obligations based on actual manufacturing, filling, labelling, quality-control or warehousing activities, and maintain CGMP records.

Authorization of a business facility does not mean that an individual is professionally qualified to practise. States generally regulate pharmacist licences and pharmacy facilities separately. In the California example, a pharmacy must have a PIC; when a local pharmacy’s PIC leaves, the pharmacy must notify the Board and nominate a replacement within 30 days, and the replacement PIC must be approved by the Board. This rule applies only in California and must not be recast as a nationwide staffing-ratio or education requirement.

Wholesalers and 3PLs may also be subject to state-level responsible-person requirements. California requires a wholesaler to be managed by a DRIC and each 3PL business location to be managed by a responsible manager; written notification procedures apply when these individuals leave. A manufacturing business should demonstrate qualified personnel, training and clearly assigned quality-management responsibilities from a CGMP perspective, rather than assume that an individual pharmacist licence automatically covers manufacturing, wholesaling or controlled-substance activities.

— Check, state by state, the individual qualifications and replacement rules for pharmacists, PICs, designated representatives and responsible managers.

State-level rules determine address licensing for pharmacy and wholesale premises. FDA advises checking the active wholesaler/3PL licence in the state where the business operates; FDA’s annual reporting database records licences by facility, so a group with multiple warehouses, states or business locations should not rely on a single head-office certificate.

Manufacturing premises should maintain appropriate facilities, equipment, cleaning and control capabilities under a CGMP quality system. The FDA pages reviewed do not specify a uniform area or capital threshold applicable to all products, and projects must not supply one themselves. The California example distinguishes an address update from an actual relocation: the former may be handled through a licence-amendment procedure, while the latter, like a change of ownership, requires a new application.

— Maintain, for each location, the licence number, scope of activities, responsible person, state licence status and inspection evidence.

It is advisable to first classify the activities and map state licensing requirements, then prepare materials for each authority in parallel. FDA drug establishment registration and listing are submitted through electronic structured product labelling (SPL); FDA eDRLS states that registered establishments should list each drug they manufacture and intend to distribute commercially. FDA registration and listing are not a product marketing application.

State facility applications are handled using local forms and in accordance with local premises and personnel rules. The California pharmacy application page provides forms for community and nonresident pharmacies, individual/financial disclosures, ownership information and authorization information; the California wholesaler page refers to wholesaler/nonresident wholesaler applications, surety bond information and responsible-person qualifications. For controlled substances, DEA’s new-application forms distinguish retail pharmacies from business categories such as manufacturers, distributors, importers and exporters.

— Prepare entity, ownership, address, personnel, quality and supply-chain, and product materials separately for each regulatory stream.

The federal materials reviewed provide deadlines for establishment registration and drug listing, but do not provide a single schedule of business licensing fees and approval periods applicable to all states, all activities or all products. FDA DECRS expressly states that establishments should register within five days of beginning operations and renew their submissions between 1/10 and 31/12 each year; where listing information changes, eDRLS states that updates are made in months 6 and 12.

State facility licences, DEA registrations and product marketing applications each have their own fees, review processes and validity arrangements. Do not use California forms, a single state’s processing guidance or the application timeline for one product to promise a fixed nationwide timeline. Determine project budgets after checking with the relevant authorities and reviewing current application forms.

— Enter FDA, state licensing, DSCSA reporting and DEA deadlines in a compliance calendar.

Swipe horizontally to view all items

Manufacturers should keep FDA establishment registration active, renew within the specified window, update drug listings and maintain a CGMP quality system. FDA uses facility status for activities such as inspections, post-market monitoring, recalls and supply-chain resilience. CGMP noncompliance may cause a drug to be legally deemed adulterated and may lead to risks including recalls, seizure and injunctions.

Wholesalers and 3PLs should report state licences and contact information to FDA annually and report significant state or federal disciplinary actions; they should also maintain DSCSA tracing, authorized trading partner review and procedures for handling illegal products. Controlled substance registrations must be renewed before their deadlines; DEA states that even during a permitted reinstatement period, controlled substances may not be handled under an expired registration.

— Maintain registers for registration, listing, state licences, DSCSA and DEA renewals, and conduct periodic internal audits.

Do not assume that a drug business licence automatically transfers in an equity transaction. In the California example, a single transaction or series of transactions through which the transferee acquires 50% or more of the beneficial interest constitutes a change of ownership; a change of ownership or location requires a new application, submitted at least 30 days before the change. Transfers of 10% to 49% equity, among other changes, are subject to a licence-amendment procedure.

Changes to responsible persons, addresses and controlled substance registrations must also be handled separately. In California, departures of PICs, DRICs and 3PL responsible managers generally must be reported within 30 days; a DEA address change requires state licensure for the new address first. FDA registration, listing and DSCSA reports should also be updated in parallel.

— Before a transaction, analyse the change procedures for ownership, control, location, responsible persons and related registrations, item by item for each state of operation.

Product marketing authorisation is separate from business or pharmacy licensure. FDA explains that a new drug generally needs an approved NDA before it is commercialized in the United States; imported drugs may require an applicable NDA, ANDA, BLA, OTC monograph or IND. Establishment registration, drug listing or an NDC does not mean that a product has been approved by FDA or that FDA has verified the information.

Before importing drugs manufactured, repackaged or relabelled by a foreign establishment, or drugs from a foreign salvage establishment, the establishment must register with FDA, renew annually, identify known importers and list finished drugs; imported drugs must also comply with labelling and CGMP requirements. The specific FDA rules for exports of ordinary human drugs have not been fully verified in this draft; it has only confirmed that DEA Form 225 covers registration of exporters of controlled substances.

A product’s marketing status, a state licence or FDA registration does not by itself authorise the handling of controlled substances. DEA separates Form 224 for pharmacies from Form 225 for manufacturers, distributors, importers and exporters; the applicable category, location and state prerequisites must be confirmed individually.

— Check the marketing pathway, import materials, labelling, listing, CGMP and applicable DEA registration for each product.